{"title":"Short-term efficacy and safety of enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma regardless of cisplatin eligibility.","authors":"Takuji Hayashi, Atsunari Kawashima, Yoshiyuki Yamamoto, Yu Ishizuya, Hiromu Horitani, Shunsuke Inoguchi, Yuki Horibe, Nesrine Sassi, Yujiro Hayashi, Takeshi Ujike, Kosuke Nakano, Osamu Miyake, Hitoshi Takayama, Koji Yazawa, Kenji Tsutsui, Yutaka Kurahashi, Wataru Nakata, Toshihisa Asakura, Tetsuya Murakawa, Koichi Okada, Masashi Nakayama, Taigo Kato, Koji Hatano, Norio Nonomura","doi":"10.1093/jjco/hyag117","DOIUrl":"10.1093/jjco/hyag117","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the short-term efficacy and safety of enfortumab vedotin plus pembrolizumab (EV + P) as a first-line systemic therapy for patients with advanced urothelial carcinoma (UC) in real-world practice, with a focus on cisplatin (CDDP) eligibility.</p><p><strong>Methods: </strong>Seventy-six patients who received EV + P treatment for advanced UC at 13 institutions between November 2024 and March 2025 were retrospectively included in this study. We collected the clinical characteristics and treatment data of the patients and assessed treatment response, progression-free survival (PFS), and adverse events (AEs). Patients were divided into two groups based on CDDP eligibility, and both efficacy and safety were compared between the groups.</p><p><strong>Results: </strong>The median observation period was 5.56 (IQR, 4.77-6.21) months. Complete response was achieved in 6 (7.9%) patients receiving EV + P, partial response in 40 (52.6%), stable disease in 20 (26.3%), and progressive disease in 10 (13.2%). Six-month and median PFS rates were 80.6% and not reached, respectively. AEs of any grade and grade ≥3 occurred in 59 (77.6%) and 25 (32.9%) patients, respectively. The most frequently observed AE was skin disorders, which occurred in 36 (47.4%) patients; no grade 5 AEs were observed. Treatment response, PFS, and the cumulative incidence of AEs did not differ between CDDP-ineligible and CDDP-eligible patients.</p><p><strong>Conclusions: </strong>The short-term efficacy of EV + P treatment seemed comparable to that in previous reports, and the safety profile was acceptable, regardless of CDDP eligibility.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1412-1419"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13766716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of severe postoperative complications on oncologic outcomes after curative resection for stage I-III colorectal cancer: a multicenter study.","authors":"Shintaro Hashimoto, Tetsuro Tominaga, Keisuke Noda, Toshio Shiraishi, Hiroki Katayama, Shoko Tei, Taiji Hida, Kazuki Motoyama, Shoto Yamazaki, Takashi Ohnoda, Hiroshi Maruta, Yuma Takamura, Rika Ono, Nobuhito Ogata, Makoto Hisanaga, Mitsutoshi Ishii, Masaaki Moriyama, Hidetoshi Fukuoka, Kazuo To, Kaido Oishi, Takashi Nonaka, Keitaro Matsumoto","doi":"10.1093/jjco/hyag126","DOIUrl":"10.1093/jjco/hyag126","url":null,"abstract":"<p><strong>Background: </strong>Severe postoperative complications (Clavien-Dindo [CD] grade ≥ 3) may compromise long-term oncologic outcomes after colorectal cancer (CRC) surgery, but their impact across all pathological stages remains unclear.</p><p><strong>Methods: </strong>We retrospectively analyzed 1990 patients who underwent curative resection for pStage I-III CRC at six hospitals (2016-2021). Multivariable Cox proportional hazards models were used to evaluate recurrence-free survival (RFS), overall survival (OS), cancer-specific survival (CSS), and time to recurrence (TTR). Stratified analyses were performed by pathological stage and complication type (intra-abdominal infectious complications [IAI] vs. non-IAI), and a 30-day landmark analysis was conducted.</p><p><strong>Results: </strong>CD ≥3 complications occurred in 128 patients (6.4%). On multivariable analysis, CD ≥3 complications were independent adverse prognostic factors for RFS (hazard ratio [HR] 1.84, P < .001), OS (HR 2.52, P < .001), and CSS (HR 2.04, P = .024), but not for TTR (HR 1.22, P = .451). Stage-stratified analyses showed significant associations with worse RFS and OS in pStage II-III, with trends in pStage I. CSS was significantly worse in pStage III (HR 3.06, P < .001). TTR showed no significant association with CD ≥3 complications in any pStage. IAI complications were independently associated with worse CSS (HR 2.21, P = .039), whereas non-IAI complications were not. These adverse effects persisted after 30-day landmark analysis.</p><p><strong>Conclusions: </strong>CD ≥3 complications independently worsen RFS, OS, and CSS but do not significantly affect TTR after curative resection for pStage I-III CRC. IAI complications are particularly associated with worse cancer-specific mortality. This discordance suggests that severe complications may not primarily accelerate recurrence itself, but may instead impair survival after recurrence, highlighting possible mechanisms beyond direct recurrence acceleration.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1317-1327"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148761185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A multicenter randomized phase III trial to evaluate the value of omission of elective neck dissection for T3-T4aN0 laryngeal cancer: JCOG2407 (JALNECK).","authors":"Kota Kawabata, Yuki Saito, Akihiro Homma, Nobuhiro Hanai, Naoki Nishio, Yoshitaka Honma, Yosuke Ariizumi, Kaori Hashimoto, Shintaro Beppu, Takashi Mukaigawa, Riku Kajikawa, Keita Sasaki, Haruhiko Fukuda, Naomi Kiyota","doi":"10.1093/jjco/hyag121","DOIUrl":"10.1093/jjco/hyag121","url":null,"abstract":"<p><p>Total laryngectomy with paratracheal dissection and elective lateral neck dissection (ELND) is the standard surgical procedure for T3-T4aN0 laryngeal cancer. However, ELND is associated with increased surgical invasiveness, higher risk of postoperative complications, and long-term functional impairment. Although previous studies suggest that ELND omission may reduce postoperative complications, including pharyngocutaneous fistulas and deterioration in quality of life (QOL), its impact on prognosis remains controversial. Therefore, we designed a multicenter, randomized phase III trial (JCOG2407) to confirm the non-inferiority of total laryngectomy with paratracheal dissection alone compared to surgery including ELND for T3-T4aN0 laryngeal cancer. The primary endpoint is overall survival. The secondary endpoints include short-term outcomes, postoperative complications, functional assessments, and QOL. A total of 280 patients from 39 institutions will be enrolled over 5 years. This trial has been registered with the Japan Registry of Clinical Trials (study number: jRCT1030250729).</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1443-1449"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13766706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paloma Salvador-Sáenz, Pablo A Álvarez-Reyes, Juan J Gómez-Herrera, Waleska Salcedo-Mercado
{"title":"Extramedullary multiple myeloma simulating lymphoproliferative disease on multimodality imaging.","authors":"Paloma Salvador-Sáenz, Pablo A Álvarez-Reyes, Juan J Gómez-Herrera, Waleska Salcedo-Mercado","doi":"10.1093/jjco/hyag127","DOIUrl":"10.1093/jjco/hyag127","url":null,"abstract":"<p><p>A 77-year-old male with monoclonal gammopathy of undertermined significance presented with multiple bulky extraosseous soft-tissue masses on imaging tests, mimicking radiological features of lymphoma. Ultimately, a diagnosis of multifocal extraosseous multiple myeloma was established, highlighting the need for comprehensive clinical and diagnostic correlation to ensure appropriate management.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1461-1462"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-term care needs and service use in terminally ill patients with cancer: a nationwide claims data study.","authors":"Richi Takahashi, Takaaki Konishi, Yoko Nakazawa, Daisuke Fujisawa","doi":"10.1093/jjco/hyag130","DOIUrl":"10.1093/jjco/hyag130","url":null,"abstract":"<p><strong>Background: </strong>Terminally ill patients with cancer may have difficulty using Japan's public long-term care insurance system because functional decline often occurs rapidly near death. We examined care-need levels, service use, and factors associated with timely service use in this population.</p><p><strong>Methods: </strong>We used anonymized long-term care insurance claims data from January 2018 to August 2025. Patients who died of cancer and whose first observed certification was granted within 1 year before death were included. Certification levels, certification period, and service use were described. Logistic regression examined factors associated with service use within 30 days after first certification.</p><p><strong>Results: </strong>Among 10 491 patients, 17.8% were initially classified as support levels 1 and 2, and 62.0% were first certified within 3 months before death. Overall, 6740 (64.2%) used long-term care services during observation, and 4822 (46.0%) used services within 30 days. Compared with patients certified 6 to ≤ 12 months before death, those certified closer to death had higher odds of service use within 30 days: adjusted odds ratios were 1.63 (95% CI, 1.43-1.84) for ≤ 1 month, 1.23 (1.09-1.40) for 1 to ≤ 3 months, and 1.17 (1.02-1.34) for 3 to ≤6 months. Higher initial care-need levels were also associated with greater service use within 30 days, peaking at care-need level 2 (5.73; 4.78-6.88).</p><p><strong>Conclusions: </strong>Many patients were first certified shortly before death. Certification closer to death was associated with prompt service use, possibly reflecting urgent care coordination. Earlier information provision and timely certification may help patients access long-term care services before death.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1380-1386"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group).","authors":"Yoshinori Ikehata, Naotaka Nishiyama, Makito Miyake, Nobutaka Nishimura, Kita Yuki, Soichiro Shimura, Yuta Inoue, Takashi Matsumoto, Shugo Yajima, Yoshiyuki Nagumo, Shuichi Morizane, Takuma Sato, Masato Fujii, Tomokazu Sazuka, Shingo Hatakeyama, Katsuyoshi Hashine, Atsushi Yamagishi, Rikiya Taoka, Yoshiyuki Matsui, Kiyohide Fujimoto, Hiroyuki Nishiyama, Keiichiro Mori, Takahiro Kimura, Hiroshi Kitamura","doi":"10.1093/jjco/hyag124","DOIUrl":"10.1093/jjco/hyag124","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of non-muscle-invasive bladder cancer (NMIBC) recurrence after a prolonged disease-free interval following intravesical Bacillus Calmette-Guérin (BCG) therapy remains unclear. This multicenter study evaluated the impact of late recurrence after BCG therapy on oncological outcomes.</p><p><strong>Methods: </strong>This retrospective multicenter study used the Japan Urological Oncology Group database. Among 3226 patients treated with intravesical BCG for NMIBC, 238 with non-muscle-invasive intravesical recurrence ≥1 year after initial BCG therapy were analyzed, after excluding those with muscle-invasive recurrence at first recurrence. Patients were stratified by time to recurrence: 1-2 years and ≥ 2 years. Progression-free survival (PFS) and cancer-specific survival (CSS) were assessed using Kaplan-Meier and Cox proportional hazards analyses.</p><p><strong>Results: </strong>During a median follow-up of 72.7 months, the 5-year PFS and CSS rates were 90.8% and 91.5%, respectively. PFS did not differ significantly between the 1-2-year and ≥ 2-year recurrence groups (log-rank p = 0.300). In contrast, recurrence ≥2 years was associated with significantly worse CSS than recurrence at 1-2 years (log-rank P = .018) and was a significant predictor of worse CSS in univariate analysis (hazard ratio, 8.06; 95% confidence interval, 1.02-62.6; P = .047). Repeat BCG therapy did not significantly improve PFS or CSS in patients with recurrence ≥2 years.</p><p><strong>Conclusions: </strong>NMIBC recurrence occurring ≥2 years after initial BCG therapy may be associated with poorer cancer-specific survival despite similar progression-free survival. Late recurrence should not automatically be considered a favorable prognostic subgroup, and careful surveillance and risk stratification are warranted.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1420-1427"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148684632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards.","authors":"Gaku Okumura, Soichiro Yoshida, Kohei Hirose, Shugo Yajima, Wei Chen, Hiroyuki Sato, Akihiro Hirakawa, Motohiro Fujiwara, Yuki Arita, Hiroshi Fukushima, Yosuke Yasuda, Hajime Tanaka, Hitoshi Masuda, Yasuhisa Fujii","doi":"10.1093/jjco/hyag133","DOIUrl":"10.1093/jjco/hyag133","url":null,"abstract":"<p><strong>Background: </strong>The phase 3 THOR trial (cohort 1) showed improved overall survival (OS) and progression-free survival (PFS) with erdafitinib versus chemotherapy in FGFR2/3-altered advanced urothelial carcinoma after prior programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) inhibitor therapy. When the assumption of proportional hazards (PH) is violated, a single hazard ratio (HR) may be difficult to interpret.</p><p><strong>Methods: </strong>We derived reconstructed individual patient data (rIPD) for OS and PFS from published Kaplan-Meier curves. PH was assessed using scaled Schoenfeld residuals and log-log plots. We fit Bayesian piecewise-exponential models with administrative censoring at τ = 24 months (OS; cut-point 12 months) and τ = 12 months (PFS; cut-point 6 months). We reported interval-specific HRs, landmark survival differences (ΔOS, ΔPFS), number needed to treat (NNT), restricted-mean survival time (RMST), and posterior probabilities for clinically meaningful thresholds.</p><p><strong>Results: </strong>Statistical diagnostics indicated that the PH assumption was violated for both OS and PFS. For OS, HR was 0.59 (95% credible interval 0.41-0.84) in months 0-12 and 1.06 (0.48-2.48) in months 12-24. At 12 months, ΔOS(12) = 0.18 (0.06-0.30); conditional median NNT was 5.45. ΔRMST (0-24) = 3.02 months (0.74-5.23), with P(ΔRMST >0) = 99.5%. For PFS, the HR was 0.64 (0.45-0.89) in months 0-6 and 0.49 (0.25-1.00) in months 6-12; ΔPFS (6) = 0.16 (0.04-0.28) and ΔRMST (0-12) = 1.74 months (0.69-2.76).</p><p><strong>Conclusion: </strong>This Bayesian rIPD-based reanalysis provides PH-robust estimands, indicating early OS benefit with uncertain later effects, and favorable PFS over 0-12 months with erdafitinib.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1437-1442"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Conversion surgery for gastric cancer: current status and future perspectives.","authors":"Itaru Yasufuku, Yusuke Okuma, Syunpei Tonomura, Seito Fujibayashi, Wakana Chikaishi, Masahide Endo, Yuji Hatanaka, Masahiro Fukada, Ryuichi Asai, Yuta Sato, Jesse Yu Tajima, Akitaka Makiyama, Yoshihiro Tanaka, Nobuhisa Matsuhashi","doi":"10.1093/jjco/hyag137","DOIUrl":"10.1093/jjco/hyag137","url":null,"abstract":"<p><p>Conversion surgery, defined as surgical resection with curative intent after a favorable response to systemic chemotherapy in patients with initially unresectable gastric cancer, has attracted considerable attention as a potential treatment strategy for metastatic disease. Observational studies suggest that long-term survival may be achieved when R0 resection is accomplished. However, the therapeutic landscape has changed with advances in systemic treatment, including immune checkpoint inhibitor-based regimens. Recent evidence indicates that some patients who respond well to modern systemic therapies may achieve prolonged survival without surgery. Emerging observational data also suggest that, among patients with profound tumor regression or complete response to chemotherapy, overall survival may not differ substantially between those undergoing surgery and those continuing systemic therapy alone, raising important questions regarding the necessity of conversion surgery in current clinical practice. Accordingly, the Japanese Gastric Cancer Treatment Guidelines 2025 concluded that evidence remains insufficient to make a clear recommendation regarding conversion surgery. This review summarizes the concept and definition of conversion surgery, outlines the resectability classifications proposed by the Japan Clinical Oncology Group, and critically reviews evidence from observational studies and prospective trials, with particular attention to chemotherapy responders treated with or without surgery. In the modern treatment era, conversion surgery remains a promising approach; however, whether it offers a survival advantage over continued systemic chemotherapy has not been established. Clarification of its appropriate role in metastatic gastric cancer requires evidence from prospective randomized trials.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1299-1308"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A single-arm phase III trial evaluating the non-inferiority of less-intensive surveillance for early gastric cancer: JCOG2504 (less-surveillance EGC).","authors":"Kota Kawabata, Tsutomu Hayashi, Rie Makuuchi, Takanobu Yamada, Masayuki Yokoyama, Takeshi Uozumi, Noriko Mitome, Haruhiko Fukuda, Yukinori Kurokawa, Narikazu Boku, Takaki Yoshikawa","doi":"10.1093/jjco/hyag123","DOIUrl":"10.1093/jjco/hyag123","url":null,"abstract":"<p><p>Patients with pathological stage I (pStage I) gastric cancer (GC) have a very low recurrence risk after curative resection. Nevertheless, intensive postoperative surveillance, similar to that for advanced disease, is widely practiced despite the unclear survival benefit. Previous studies have not demonstrated improved overall survival (OS) through early detection of asymptomatic recurrence; however, intensive surveillance may cause unnecessary radiation exposure, patient burdens, and increased healthcare costs. Therefore, evidence is needed to determine whether a less-intensive risk-adapted surveillance strategy is clinically acceptable for this low-risk population. We designed a single-arm phase III trial (JCOG2504) to confirm the non-inferiority of less-intensive surveillance compared to standard surveillance in patients with pStage I GC after curative resection. The primary endpoint is OS. A total of 605 patients from 66 institutions will be enrolled over 3 years. The trial has been registered in the Japan Registry of Clinical Trials (study number: jRCT1030250844).</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1450-1454"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hisaki Aiba, Ayano Aso, Alberto Righi, Marco Gambarotti, Paolo Spinnato, Eiji Nakata, Marco Focaccia, Giorgio Frega, Hiroaki Kimura, Hideki Murakami, Davide Maria Donati, Costantino Errani
{"title":"Influence of pathologic fractures on oncologic outcomes in extremity Ewing sarcoma: a single-institution retrospective study.","authors":"Hisaki Aiba, Ayano Aso, Alberto Righi, Marco Gambarotti, Paolo Spinnato, Eiji Nakata, Marco Focaccia, Giorgio Frega, Hiroaki Kimura, Hideki Murakami, Davide Maria Donati, Costantino Errani","doi":"10.1093/jjco/hyag115","DOIUrl":"10.1093/jjco/hyag115","url":null,"abstract":"<p><strong>Background: </strong>Pathologic fractures occur in 5%-10% of patients with Ewing sarcoma and may influence the local treatment strategies. However, their prognostic impact remains unclear. This study evaluated the clinical course of patients with extremity Ewing sarcoma and pathologic fractures using a propensity score-matched analysis.</p><p><strong>Methods: </strong>This retrospective single-institution study reviewed 149 patients with extremity Ewing sarcoma treated between 2003 and 2020, including 12 patients (8.1%) with pathologic fractures. For comparison with patients without pathologic fractures, a 1:3 propensity score-matched control group (n = 36, adjusted group) was constructed.</p><p><strong>Results: </strong>Among the 12 patients, limb-sparing surgery was performed in 11 patients (91.7%), and limb salvage was finally achieved in 10 patients (83.3%). Three-year overall survival was 75.0% in patients with pathologic fractures, and 78.8% (unadjusted, P = .62) and 82.0% (adjusted, P = .60) in patients without pathologic fractures. Local recurrence was observed in two patients (16.7%) in the pathologic fracture group; both had a poor histologic response.</p><p><strong>Conclusions: </strong>In this cohort, pathologic fractures were not associated with a statistically significant difference in oncological outcomes. Limb-sparing surgery may be considered in selected patients, particularly when preoperative treatment is effective. However, the small number of the patients with the fracture limits statistical power and generalizability of the results.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1349-1355"},"PeriodicalIF":2.5,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148535934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}